MKI67 and breast carcinoma: Previous TMAs (13, 61) have allowed us to detect levels of mitotic kinases in breast cancer tissues of patients of different races and ethnicities and correlate their levels with pathologic subtypes of breast cancer (e.g., PR, ER, HER2, and Ki-67), as well as surrogate markers of metastasis (e.g., vimentin).